Oxylabs’ $130 Million Deal Highlights 5 Lessons From Building a Rule-Free Industry

A decade after its founding, the public web data firm accepted outside capital for the first time — a $130 million investment that pushed its valuation to $3.6 billion — and its leaders say the path to that deal was shaped by choices most startups in new sectors ignore.

Oxylabs’ milestone underscores how companies that create whole markets must invent not only products but business practices. When the company began in 2015, automated access to public web information was a niche few understood and regulators had not yet caught up. That vacuum meant early teams had to solve technical, legal and commercial problems without playbooks. The choices they made over more than 10 years — about how to experiment, protect ideas, manage customers, and steward their industry — paved the way for the recent financing and a valuation that led the publicly tracked online data sector.

One essential trade-off the firm learned: test boldly, but safeguard the stable offering that customers rely on. In fast-moving fields you must try many pilots to see what sticks, but those trials can’t come at the expense of the product that keeps revenue flowing. Customers may forgive occasional feature flops, but repeated disruptions to core workflows drive churn and invite competitors to seize the opening. A former engineering leader I spoke with recommended isolating experimental code behind feature switches and keeping a small, well-tested baseline that users can count on.

Another early priority was building an intellectual property workflow rather than treating patent filings as an afterthought. Turning lab notebooks and prototypes into a structured filing process, supported by lawyers who understand both the tech and the market, clarifies what is truly unique and creates a deterrent against copycats. Legal counsel I consulted advised filing provisional claims quickly, while documenting the work in detail so teams can later demonstrate why a technique or system is defensible — which also makes negotiating disputes far easier.

Companies operating in poorly regulated markets should act as if oversight is already present. Instituting robust customer identity checks, screening how data will be used and maintaining strong information-security practices from day one pays off later when investors and auditors do their homework. That discipline often means passing on revenue from questionable deals, but the credibility it builds compounds: one small, early refusal can make later diligence and partnership approvals smoother. An outside compliance expert said firms that bake screening into their processes rarely face existential regulatory surprises.

When the industry’s reputation is shaky, individual firms can’t repair it alone. Leaders should collaborate to set standards and certify participants, rather than waiting for regulators to impose rules. In this sector, a coalition of companies eventually created an ethics-oriented initiative aimed at defining acceptable collection practices; participating firms report that having a shared code reduced bad actors’ influence and improved public perception. And finally, money matters — but timing and prudence matter more. Oxylabs’ founders emphasize that fiscal restraint over many years left them in a position to accept capital only on terms they found favorable, rather than chasing early rounds that might have diluted control or forced short-term pivots. An investor I spoke with said disciplined operators tend to secure better deals because they can demand terms instead of needing them.

Building in an unruled market is messy and risky, but these choices — protecting a reliable core, codifying inventions, enforcing customer checks, raising collective standards and managing cash carefully — are the moves that help a market-creator survive and eventually attract sizable, strategic investment.